Biomedicines (Oct 2022)

Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors

  • Sören Weidemann,
  • Nessar Ahmad Noori,
  • Maximilian Lennartz,
  • Viktor Reiswich,
  • David Dum,
  • Anne Menz,
  • Viktoria Chirico,
  • Claudia Hube-Magg,
  • Christoph Fraune,
  • Ahmed Abdulwahab Bawahab,
  • Christian Bernreuther,
  • Ronald Simon,
  • Till S. Clauditz,
  • Guido Sauter,
  • Andrea Hinsch,
  • Simon Kind,
  • Frank Jacobsen,
  • Stefan Steurer,
  • Sarah Minner,
  • Eike Burandt,
  • Andreas H. Marx,
  • Till Krech,
  • Patrick Lebok,
  • Franziska Büscheck,
  • Doris Höflmayer

DOI
https://doi.org/10.3390/biomedicines10102507
Journal volume & issue
Vol. 10, no. 10
p. 2507

Abstract

Read online

As a result of its expression in corresponding normal cell types, inhibin alpha (INHA) is used as an immunohistochemical marker for adrenocortical neoplasms and testicular or ovarian sex cord stromal tumors. However, other tumors can also express INHA. To comprehensively determine INHA expression in cancer, a tissue microarray containing 15,012 samples from 134 different tumor types and subtypes was analyzed by immunohistochemistry. INHA positivity was found in 72 of 134 tumor categories, including 26 categories with ≥1 strongly positive case. A moderate to strong INHA positivity was found in 100% of 37 granulosa cell tumors of the ovary, 100% of 43 other sex cord stromal tumors of the ovary/testis, 100% of 31 granular cell tumors, 78.5% of 28 adenomas, 44% of 25 carcinomas of the adrenal cortex, and 46.7% of 15 pancreatic acinar cell carcinomas. At least a weak INHA positivity was seen in <33% of cases of 46 additional tumor entities. In summary, these data support the use of INHA antibodies for detecting sex cord stromal tumors, granular cell tumors, and adrenocortical neoplasms. Since INHA can also be found in other tumor entities, INHA immunohistochemistry should only be considered as a part of any panel for the distinction of tumor entities.

Keywords